Homepage

2019/02/14MEDICAL UPDATE

Highlights from ASH 2018

by Esther Drain As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study, which compared BV+CHP vs CHOP for patients with peripheral T-cell lymphoma. In the video above, Dr Graham Collins (Oxford, UK), Dr Alison J. Moskowitz (New York, USA) and Professor Andrei Shustov (Seattle, USA) provide their highlights from the meeting.

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

By Tom Collins (author) and Hannah Chatfield (interviews) Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on risk stratification of patients...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Advances in the management of peripheral T-cell lymphoma

By Maria Dalby (article) and Esther Drain (interviews) Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is therefore urgent...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Follicular Lymphoma: Have We Made Progress?

by Tom Collins (author) and Hannah Chatfield (interview) Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphomas1 and although rarely curable, a number of treatment options exist. In an education session on current and emerging options for the treatment of FL, respectively, presentations focused on data supporting rituximab as single-agent or in combination with chemotherapy and as maintenance therapy in newly-diagnosed FL, and chemotherapy-free regimens and novel immunotherapy approaches in relapsed FL...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Phoenix and other DLBCL study updates

by Tom Collins (article) and Esther Drain (interview) Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future plans following this study

READ MORE

2019/02/01MEDICAL UPDATE

ASH 2018: Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma

by Tom Collins (article) and Hannah Chatfield (interview) The use of CAR T-cell therapy in lymphomas represents a very novel and fast-moving area of research with continuous preclinical and clinical advances...

READ MORE

2019/01/14MEDICAL UPDATE

ASH 2018: Treating CTCL in the real-world

Dr Horwitz discusses treating CTCL in the real-world. 

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Variety of approaches can work in oligometastatic disease

By Thomas R Collins / Interviewer Esther Drain Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Lung cancer stigma is detrimental to patient care

Interviewer Esther Drain Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients' care.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Importance of QOL outcome measures in clinical trials

Interviewer Esther Drain WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

READ MORE